S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged

Cathie Wood Likes UiPath Stock Over NVDA, Should You?

Cathie Wood

Key Points

  • Cathie Wood is one of the notable investors who has not benefited from the meteoric rise of NVDA stock. 
  • Wood is partial to UiPath, the world's largest provider of end-to-end robotic process automation (RPA) and business process automation (BPA) platforms.  
  • UiPath represents the next leg of the AI journey, which Wood seems to be banking on.  
  • 5 stocks we like better than UiPath

If you missed out on the 244% gain in Nvidia Corporation NASDAQ: NVDA in the past 12 months, you have impressive company. Cathie Wood, head of Ark Investment Management, sold NVDA stock in 2023 and never looked back.  

Critics of Wood, of which there are many, will see this as more ammunition for their critiques of her investment style. Detractors point most commonly to her Ark funds' heavy concentration in highly volatile disruptive technology stocks, the lofty valuations of many top picks, and – in some cases – underwhelming short-term performance.  

But could this be a tortoise and hare situation where Wood will, over time, enjoy the last laugh? Wood hasn't abandoned artificial intelligence stocks. She's just taking a different path. Whether or not she succeeds will depend on one stock that her funds have been buying hand over fist, that of UiPath Inc. NYSE: PATH.  

A Path to Future Riches? 

Wood started buying PATH stock in April 2022, which coincided with the company going public. She has continued to hold or add to her position to this day. Today, UiPath is the second largest holding by share count in her signature Ark Innovation ETF NYSEARCA: ARKK.  

At the time of her first purchase, Wood expressed "high conviction in UiPath's ability to integrate Robotic Process Automation (RPA) into many business processes across large enterprises around the world." To that end, UiPath has customers in several sectors, including healthcare, banking and financial services, insurance, government, telecom, and manufacturing.  


The company's mantra is "UiPath is AI at work." Its AI software bots can help enterprise customers move from discovery to fully automated operations. Since the first quarter of its 2022 fiscal year, UiPath has grown its annualized renewal run rate (ARR) at a compound annual growth rate (CAGR) of 35% through its most recent quarter ending in September 2023.  

It's the Egg to the Chicken 

The growth of Nvidia reminds investors that the AI story is still in its early stages. That's why investors continue to rush into Nvidia. AI chips will be essential to enabling AI applications. But no chip can make an application happen with software. Perhaps that's the bet that Wood is taking on UiPath.  

The question is, should you?  

PATH stock is down more than 66% since its initial public offering (IPO). However, the stock is up 52% in the last 12 months, but the UiPath analyst ratings on MarketBeat have a Hold rating on the stock with a $22.32 consensus price target that is 6% below the price on March 4, 2024.  

Looking at the option chain for PATH stock, $23.50 seems to be a sweet spot for short-term call and put options. Going out until mid-April, traders anticipate that the stock will be range-bound around its current level.  

One catalyst could be the company's next earnings report on March 13, 2024. The company is forecasting revenue of $381 million. That's slightly below the consensus estimate of $382.84 million. Additionally, the company expects annual recurring revenue (ARR) to be between $1.45 billion and $1.455 billion.  

Should you invest $1,000 in UiPath right now?

Before you consider UiPath, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UiPath wasn't on the list.

While UiPath currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
UiPath (PATH)
3.9063 of 5 stars
$18.75-1.5%N/A-110.29Moderate Buy$27.41
NVIDIA (NVDA)
4.894 of 5 stars
$762.00-10.0%0.02%63.82Moderate Buy$940.30
ARK Innovation ETF (ARKK)N/A$42.00-2.1%N/AN/AN/AN/A
Compare These Stocks  Add These Stocks to My Watchlist 

Chris Markoch

About Chris Markoch

  • CTMarkoch@msn.com

Editor & Contributing Author

Retirement, Individual Investing

Experience

Chris Markoch has been an editor & contributing writer for MarketBeat since 2018.

Areas of Expertise

Value investing, retirement stocks, dividend stocks

Education

Bachelor of Arts, The University of Akron

Past Experience

InvestorPlace


Featured Articles and Offers

7 Must-Buy Stocks Under $20

7 Must-Buy Stocks Under $20

In this video, we highlight seven stocks under $20 that are worth a closer look.

Search Headlines: